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Abstract
The autosomal-dominant precancerous condition familial adenomatous polyposis (FAP) is caused by germline
mutations in the tumour suppressor gene APC. Consistent correlations between the site of mutations in the gene
and clinical phenotype have been published for different patient groups. We report our experiences of APC
mutation analysis and genotype-phenotype correlations in 1166 unrelated polyposis families and discuss our
results in the light of literature data. We show that the mutation detection rates largely depend on the family history
and clinical course of the disease. We present a list of 315 different point mutations and 37 large deletions
detected in 634 of the 1166 index patients. Our results confirm previously published genotype-phenotype
correlations with respect to the colorectal phenotype and extracolonic manifestations. However, 'exceptions to
the rule' are also observed, and possible explanations for this are discussed. The discovery of autosomal-recessive
MUTYH-associated polyposis (MAP) as a differential diagnosis to FAP implies that some results have to be
reinterpreted and surveillance guidelines in the families have to be reevaluated. 
Familial Adenomatous Polyposis: Experience from 
a Study of 1164 Unrelated German Polyposis Patients
Waltraut Friedl, Stefan Aretz
Institute of Human Genetics, University of Bonn, Germany
Key words:  famil ia l  adenomatous polyposis ,  APC gene,  APC mutat ions ,  genotype -phenotype correlat ions
Corresponding author: Dr. Waltraut Friedl, Institute of Human Genetics, University of Bonn, Wilhelmstrasse 31, D-53111 Bonn,
Germany, phone +49 (0) 228-287-2334, fax +49 (0) 228-287-2380, e-mail: waltraut.friedl@ukb.uni-bonn.de 
Submit ted:  29 August  2005
Accepted:  2  September 2005
Introduction
Familial adenomatous polyposis (FAP, OMIM
+175100) is a clinical diagnosis that is typically based
on the presence of more than 100 colorectal adenomas.
If untreated patients develop colorectal cancer at a mean
age of 40 years [1]. Other gastrointestinal features
(duodenal adenomas, fundic gland cysts) and
extragastrointestinal manifestations, including congenital
hypertrophy of the retinal pigment epithelium (CHRPE),
desmoids and osteomas are frequently described. 
FAP is an autosomal-dominant disorder caused by
germline mutations in the tumour suppressor gene APC
on chromosomal region 5q22 [2, 3]. The APC gene
encodes a multifunctional protein of 2843 amino acids
that plays a major role in controlling cell cycle
progression, migration, differentiation and apoptosis
(review in [4, 5]). Germline mutations in the APC gene
were also detected in some families with an attenuated
polyposis phenotype (AAPC, AFAP) who present with
less than 100 adenomas and a later age at onset
compared to patients with typical FAP [6]. 
During the last few years correlations between site
of mutation in the APC gene and clinical phenotype
have been reported on patient groups of different sizes
[7-12]. Most of the published correlations proved to
be statistically consistent, but there were also 'deviations
from the rule' when individual cases were considered. 
Recently a polyposis syndrome characterised by
multiple adenomatous polyps and an autosomal-
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-recessive mode of inheritance has been identified that
is caused by germline mutations in the base excision
repair gene MUTYH (MYH) [13]. Biallelic MUTYH
mutations have been identified in up to 40% of patients
in whom no mutation in the APC gene was identified
[14-16]. This new adenomatous polyposis condition is
designated as MUTYH-associated polyposis (MAP;
OMIM #608456) and has to be considered as
a differential diagnosis of the autosomal-dominant FAP. 
In this review we report on our experience of mutation
analysis in the APC gene and genotype-phenotype
correlations in 1166 unrelated patients with a clinical
diagnosis of FAP or multiple adenomatous polyposis
consistent with AAPC and discuss our results in the light
of literature data. 
Phenotype classification
Since 1991, blood samples from 1166 unrelated
patients with a clinical diagnosis of typical or attenuated
FAP (AAPC) have been referred to the Institute of
Human Genetics, University of Bonn for mutation
analysis in the APC gene. Clinical information on 2066
patients from the 1166 families was obtained during
genetic counselling sessions, from a questionnaire, or
through telephone interviews and/or medical records.
The study was approved by the Ethics Commission of
University Hospital, Bonn. 
Colorectal phenotype
The classification of different FAP phenotypes was
based on the number of colorectal adenomas, age at
diagnosis of FAP and occurrence of CRC (Table 1). The
FAP phenotype was classified as typical when the patient
presented with more than 100 colorectal adenomas
before the age of 35; in cases of unavailable or unclear
colonoscopic data, the classification was based on the
occurrence of clinical bowel symptoms before the age
of 35, or a diagnosis of CRC before the age of 45. The
diagnostic criterion for the attenuated phenotype (AAPC)
was the occurrence of a smaller number of adenomas
(10-100) after the age of 25 or more than 100
adenomas diagnosed for the first time after the age of
45. When the polyp number was unknown, AAPC was
assigned if the first symptoms or diagnosis of CRC
occurred after the age of 45. The phenotype was
considered severe in patients who developed more than
a thousand adenomas or polyposis-related bowel
symptoms before the age of 15, or when diagnosed with
polyps before the age of 10. The phenotype was
classified as atypical in patients who did not meet the
criteria for either typical or attenuated FAP, when an
unambiguous attribution was impossible. Patients with
an atypical course usually presented with more than 100
polyps, diagnosed between 35 and 45 years of age; in
addition, cases with an obvious discrepancy between
the age at diagnosis (symptoms) and the number of
colorectal adenomas were also considered atypical. If
clinical information on the colorectal disease was not
available or not sufficient to determine the extent of
colorectal polyposis, the phenotype was considered
'unknown'. 
Family history
Due to the existence of the recently discovered
MUTYH-associated polyposis [13] we considered it
important to allow for the mode of inheritance in the
families: index patients were classified as familial cases
with autosomal-dominant inheritance when at least two
patients (one of them a parent of the index patient) were
affected in the family. An autosomal-recessive mode of
inheritance was considered when the index patient had
at least one affected sibling, but no affected parents or
children. Cases where the index patient was the only
affected person known in the family, or no information
on other family members (parents, siblings, children) was
available, were classified as 'single cases'. Index patients
were classified as de novo mutations only if an APC
mutation was identified and both parents were either
healthy until an advanced age, or when the mutation
was excluded in both parents, irrespective of whether or
not the index patient had affected children [17]. 
Mutation analysis in the APC gene
Point mutations
Genomic DNA extracted from peripheral blood
samples was used for mutation analysis. We started the
search for germline mutations in the APC gene in 1991
by SSCP and heteroduplex analysis. To date, we apply the
protein truncation test (PTT) for detection of mutations in
exon 15 in four overlapping fragments, essentially as
described [18], using an in vitro transcription translation
kit (Promega, Mannheim, Germany) in the presence of
35S-Methionine (Amersham). Denaturing high-performance
liquid chromatography (DHPLC) is used for screening of
exons 1-14 and the first 400 bp of exon 15 (WAVE,
Transgenomics). PCR fragments showing variant bands
by either method were sequenced on an ABI prism 377
or ABI 3100 automated sequencer (Applied Biosystems,
Darmstadt, Germany) using the cycle sequencing
procedure and the BigDye terminator kit version 2.0 or
1.1, respectively. Some of the APC mutation negative
patients from the first series were reexamined using the
more up-to-date procedures described. 
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Table 1. APC mutation detection rate according to colorectal phenotype and family history
Colorectal phenotype
all severe typical atypical attenuated unknown
Patients 1166 33 504 85 407 137
point mutation 597 25 384 38 93 57
large deletion 37 30 2 4 1
all mutations 634 25 414 40 97 58
Mutation detection rate 54% 76% 82% 47% 24% 42%
Familial cases (dominant) 558 13 326 38 131 50
Mutation detection rate 73% 85% 85% 71% 49% 56%
Familial cases (recessive) 27 1 2 6 17 1
Mutation detection rate 0%
De novo mutations 63 10 46 – 6 1*
Mutation detection rate 100%
Single cases 255 7 65 26 127 30
Mutation detection rate 30% 43% 60% 27% 14% 30%
Unknown 263 2 66 15 125 55
Mutation detection rate 34% 50% 80% 40% 7% 36%
* The diagnosis of FAP was suspected because of osteomas in a child with normal colonic phenotype at the age of 11. In this patient a de novo frameshift mutation 
in codon 1551 was proven.
We identified a germline point mutation in the APC
gene in 597/1166 patients (51.2%) (Table 1). Overall,
we found 315 different point mutations (Supplementary
table 1). Most of the mutations are spread over the first
half of the gene. Of note, no mutation was detected
in exons 1 and 2 (Fig. 1). Two hot spot mutations at
codons 1309 and 1061 are evident. 
Most mutations were truncating, including 364
frameshift mutations, 182 nonsense mutations and 38
mutations in the highly conserved splice site sequences.
In addition, in 13 patients we identified 8 different
missense mutations and three different silent
substitutions; seven of these single base substitutions
were localised at exonic boundaries. For four
substitutions localised in exon 4 and exon 14 we could
demonstrate by RNA analysis that they actually affect
splicing and thus cannot be considered missense
mutations or silent variants [19]. 
Large genomic deletions
DNA samples from patients negative for point
mutations in the APC gene were examined for the
presence of large genomic deletions or duplications
using MLPA (multiplex ligation-dependent probe
amplification) (SALSA P043 APC exon deletion test kit;
MRC Holland, Amsterdam) according to the
manufacturer’s recommendations, as described [20]. 
Five large genomic deletions encompassing the APC
gene had been detected earlier by haplotype analysis;
one of them was cytogenetically visible [21, 22]. By use
of MLPA we have examined so far 401 out of the 569
patients negative for point mutations in the APC gene
for the presence of large genomic deletions or
duplications [20]. Altogether we have detected a total
of 37 large deletions. The deletions extend over single
exons up to the entire APC gene including the promotor
region (see Supplementary table 2 and Fig. 1). 
Mutational hot spots
The 5 bp deletion c. 3927_3931delAAAGA (at
codon 1309) was detected in 56 of the 1166 index
patients (4.8%). All except two patients with this
mutation showed typical or severe early onset polyposis;
in this combined patient group the frequency of the
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Supplementary table 1. 315 different point mutations detected in 597 out of 1166 unrelated patients suspected of FAP. (The DNA mutation
numbering is based on the cDNA sequence for APC where +1 corresponds to the A of the ATG translation initiation codon in the reference
sequence Genbank, NM_000038.2.)
Exon/Intron Codon Mutation Consequence Number 
of alleles
3 122 c.366delG p.Gly122fs 1
3 129 c.386_387insT p.Glu129fs 1
3 139 c.416_419delAAGA p.Lys139fs 1
intron 3 141 c.423-5A>G 2
intron 3 141 c.423-3T>A 1
intron 3 141 c.423-2A>T 1
intron 3 141 c.423-1G>A 1
intron 3 141 c.423-1G>T 1
intron 3 141 c.423-1G>C 1
4 141 c.423G>T p.Arg141>Ser* 2
4 142 c.426_427delAT p-Ser142fs 1
4 150 c.450_453delAGAA p.Lys150fs 2
4 151 c.453delA p.Glu151fs 1
4 152 c.455_459delAAAAG p.Glu152fs 1
4 153 c.457_458delAA p.Lys153fs 1
4 156 c.468_472delCTGGT p.Asp156fs 1
4 159 c.477C>G p.Tyr159X 2
4 161 c.481C>T p.Gln161X 1
4 170 c.509_512delATAG p.Asp170fs 4
4 171 c.509_512dupATAG p.Ser171fs 1
intron 4 177 c.531+1G>A 1
intron 4 177 c.531+5G>C 1
intron 4 177 c.531+5_531+8delGTAA 2
intron 4 178 c.532-2A>G 1
intron 4 178 c.532-1G>T 1
5 181 c.540_541insA 1
5 181 c.541C>T p.Gln181X 4
5 191 c.573dupT p.Tyr191fs 1
5 197 c.591_592delAG p.Arg197fs 1
5 203 c.607delC p.Gln203fs 2
5 213 c.637C>T p.Arg213X 7
5 214 c.641dupC p.Ala214fs 1
6 216 c.646C>T p.Arg216X 6
6 225 c.673G>T  p.Glu225X 1
6 226 c.677delA p.Lys226fs 1
6 232 c.694C>T p.Arg232X 6
6 242 c.726delA p.Pro242fs 1
intron 6 243 c.730-1G>T 2
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Exon/Intron Codon Mutation Consequence Number 
of alleles
7 264 c.790C>T p.Gln264X 1
7 267 c.799G>T p.Gly267X 1
7 271 c.812delT p.Met271fs 1
7 271 c.811_818delATGGCAAC p.Met271fs 1
7 278 c.834G>A p.Gln278 1
8 283 c.847C>T p.Arg283X 6
8 297 c.891_894delACAC p.Thr297fs 1
8 302 c.904C>T p.Arg302X 5
intron 8 311 c.933+2T>C 1
intron 8 311 c.933+1delG 1
9 314 c.940dupA p.Met314fs 1
9 332 c.994C>T p.Arg332X 9
9 340 c.1018_1019dupTC p.Ser340fs 1
9 367 c.1100_1101delCT p.Ser367fs 1
9 368 c.1102dupG p.Val368fs 1
9 374 c.1120dupC p.Ar.374fs 1
9 386 c.1158_1159delAC p.Ala386fs 1
9 398 c.1192_1193delAA p.Lys398fs 2
9 405 c.1213C>T p.Arg405X 3
9 414 c.1240C>T p.Arg414Cys 1
9 414 c.1242delC p.Arg414fs 1
9 423 c.1269G>A p.Trp423X 2
9 433 c.1297C>T p.Glu433X 2
9 436 c.1307dupA p.Asn436fs 1
intron 9 438 c.1312+2dupT 3
intron 9 438 c.1312+2T>C 1
intron 9 438 c.1312+3A>G; 2
intron 9 438 c.1312+5C>A 1
10 438 c.1313dupT p.Met438fs 1
10 445 c.1333_1334dupCA p.Gln445fs 1
10 457 c.1370C>G p.Ser457X 2
10 457 c.1370C>A p.Ser457X 2
intron 10 470 c.1409-5A>G 1
intron 10 470 c.1409-2A>C 1
intron 10 470 c.1409-2A>G 1
intron 10 470 c.1409-1G>A 1
11 471 c.1411G>T p.Gly471X 1
11 471 c.1412delG p.Gly471fs 1
11 473 c.1417delC p.Gln473fs 1
11 478 c.1434delA p.Ile478fs 1
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Exon/Intron Codon Mutation Consequence Number 
of alleles
11 493 c.1479_1483delCAGTA p.Tyr493fs 1
11 499 c.1495C>T p.Arg499X 8
11 516 c.1548G>C p.Lys516Asn 1
12 517 c.1549-1G>A 1
12 519 c.1555dupC p.Leu519fs 1
12 527 c.1581_1590del10bp p.Arg527fs 1
12 528 c.1584dupA p.Ala528fs 2
12 538 c.1613A>T p.Glu538Val 1
12 541 c.1621C>T p.Gln541X 1
12 542 c.1624C>T p.Gln542X 1
13 554 c.1660 C>T p.Arg554X 10
13 561 c.1683_1684delGA p.Lys561fs 1
13 562 c.1685_1686insCC p.Thr562fs 1
13 563 c.1688delT p.Leu563fs 1
13 564 c.1690C>T p.Arg564X 9
13 567 c.1700_1704delGAAGT p.Gly567fs 1
13 571 c.1712delC p.Ala571fs 1
13 580 c.1737dupT p.Lys580fs 1
13 581 c.1742delA p.Lys581fs 1
13 581 c.1742A>G p.Lys581Arg 1
intron 13 582 c.1744-2A>G 1
intron 13 582 c.1744-[5_13del; 17_18del] 1
14 583 c.1748C>A p.Ser583X 1
14 592 c.1775T>G p.Leu592X 1
14 593 c.1779G>A p.Trp593X 1
14 599 c.1797C>A p.Cys599X 1
14 614 c.1840dupG p.Gly614fs 2
14 616 c.1847delT p.Leu616fs 1
14 617 c.1849delG p.Val617fs 1
14 620 c.1858_1859dupCT p.Leu620fs 3
14 621 c.1861dupA p.Thr621fs 1
14 621 c.1863_1866delTTAC p.Thr621fs 3
14 622 c.1866C>G p.Tyr622X 1
14 628 c.1884_1897dup14 p.Thr628fs 1
14 629 c.1886delT p.Leu629fs 1
14 629 c.1886dupT p.Leu629fs 1
14 629 c.1885_1886dupTT p.Leu629fs 1
14 630 c.1890delC p.Ala630fs 1
14 636 c.1907dupG p.Gly636fs 1
14 639 c.1916delT p.Leu639fs 2
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Exon/Intron Codon Mutation Consequence Number 
of alleles
14 650 c.1948G>T p.Glu650X 1
14 652 c.1956C>T p.His652* 1
14 653 c.1957A>C p.Arg653* 2
14 653 c.1957A>G p.Arg653Gly* 1
intron 14 653 c.1958+1G>T 4
intron 14 653 c.1958+1G>A 1
intron 14 653 c.1958+3A>G 2
intron 14 653 c.1959-2A>G 1
15A 653 15A: c.1959delG 1
15A 658 c.1972G>T p.Glu658X 1
15A 669 c.2005_6delTT p.Leu669fs 1
15A 685 c.2055G>A p.Trp685X 1
15A 703 c.2107delG p.Ala703fs 2
15A 703 c.2107dupG p.Ala703fs 1
15a 710 c.2130delC p.Leu710fs 1
15A 712 c.2136_2139delTTCA p.His712fs 1
15A 737 c.2209_2218del10 p.Tyr737fs 1
15A 747 c.2240C>G p.Ser747X 2
15B 757 c.2269delC p.Gln757fs 1
15B 767 c.2299C>T p.Gln767X 3
15B 770 c.2309delC p.Gln770fs 1
15B 773 c.2318_ 2319delTT p.Phe773fs 2
15B 779 c.2335_2336dupTT p.Leu779fs 2
15B 781 c.2343delC p.Pro781fs 1
15B 791 c.2373_2374delCA p.Lys791fs 2
15B 797 c.2391_2392delTG p.Gly797fs 1
15B 799 c.2396_2397delAT p.Tyr799fs 1
15B 805 c.2413 C>T p.Arg805X 3
15B 811 c.2432C>G p.Ser811X 1
15B 828 c.2483delC p.Thr828fs 1
15B 834 c.2502delC p.Ser834fs 1
15C 837 c.2510delC p.Ser837fs 1
15C 841 c.2523dupA p.Leu841fs 1
15C 843 c.2527_2530delAGTT p.Ser843fs 1
15C 849 c.2547_2548delTA p.Asp849fs 1
15C 849 c.2546_delATAGAAG p.Asp849fs 1
15C 849 c.2547_2550delTAGA p.Asp849fs 2
15C 850 c.2548delAGAA p.Arg850fs 1
15C 855 c.2563G>T p.Glu855X 1
15C 855 c.2563_2564delGA p.Glu855fs 1
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Exon/Intron Codon Mutation Consequence Number 
of alleles
15C 857 c.2570delG p.Gly857fs 1
15C 863 c.2589C>G p.Tyr863X 1
15C 871 c.2612delG p.Gly871fs 1
15C 872 c.2614_2617delACTT p.Thr872fs 1
15C 876 c.2626C>T p.Arg876X 6
15C 900 c.2698_2699insTG p.Ser900fs 1
15C 903 c.2709_2712delCAGA p.Asp903fs 1
15C 916 c.2748delA p.Thr916fs 1
15C 929 c.2787_2790delTACA p.His929fs 1
15C 932 c.2795C>G p.Ser932X 1
15C 934 c.2802_2805delTTAC p.Thr934fs 3
15C 935 c.2805C>G p.Tyr935X 6
15D 939 c.2816delA p.Lys939fs 1
15D 947 c.2840delG p.Cys947fs 1
15D 951 c.2853T>A p.Tyr951X 1
15D 951 c.2853 T>G p.Tyr951X 1
15D 962 c.2884delG p.Asp962fs 1
15D 965 c.2893_2896delAATA p.Asn964fs 3
15D 974 c.2921delG p.Gly974fs 1
15D 976 c.2926delA p.Arg976fs 1
15D 978 c.2932C>T p.Gln978X 2
15D 985 c.2953_3022del70 p.Ser985fs 1
15D 985 c.2953dupT p.Ser985fs 1
15D 997 c.2991T>G p.Tyr997X 1
15D 1000 c.3000C>G p.Tyr100X 1
15D 1010 c.3027_3028dupTA p.Ser1010fs 1
15D 1023 c.3068delC p.Thr1023fs 1
15D 1023 c.3069_3070delAC p.Thr1023fs 1
15D 1024 c.3071delC p.Pro1027fs 1
15D 1032 c.3095C>A p.Ser1032X 1
15D 1041 c.3121C>T p.Gln1041X 2
15E 1044 c.3131C>A p.Ser1044X 1
15E 1045 c.3133C>T p.Gln1045X 1
15E 1049 c.3146G>A p.Trp1049X 1
15E 1049 c.3147G>A p.Trp1049X 1
15E 1050 c.3148delG p.Ala1050fs 1
15E 1050 c.3149delC p.Ala1050fs 1
15E 1055 c.3164_3168delTAATA p.Ile1055fs 4
15E 1055 c.3164_3165delTA p.Ile1055fs 1
15E 1061 c.3183_3187delACAAA p.Lys1061fs 43
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Exon/Intron Codon Mutation Consequence Number 
of alleles
15E 1062 c.3184_3187delCAAA p.Gln1062fs 1
15E 1062 c.3186_3187delAA p.Gln1062fs 1
15E 1065 c.3193C>T p.Gln1965X 1
15E 1068 c.3202_3205delTCAA p.Ser1068fs 19
15E 1071 c.3211C>T p.Gln1071X 1
15E 1072 c.3215_3216delGTinsC p.Ser1072fs 1
15E 1075 c.3225delT p.Tyr1075fs 1
15E 1087 c.3260_3261delTC p.Leu1087fs 1
15E 1088 c.3263delA p.Gln1088fs 1
15E 1096 c.3286C>T p.Gln1096X 3
15E 1107 c.3316_3319dupGGAG p.Ala1107fs 1
15E 1114 c.3340C>T p.Arg1114X 5
15E 1121 c.3361delA p.Glu1121fs 1
15E 1127 c.3379C>T p.Gln1127X 1
15E 1129 c.3386T>C p.Leu1129Ser 1
15E 1130 c.3390T>A p.Cys1130X 1
15E 1132 c.3394delG p.Glu1132fs 1
15E 1147 c.3439dupT p.Tyr1147fs 1
15E 1147 c.3441C>G p.Tyr1147X 1
15E 1152 c.3454C>T p.Gln1152X 1
15E 1155 c.3464_3468delAAGAA p.Glu1155fs 1
15F 1156 c.3467_3470delAAGA p.Glu1156fs 4
15F 1157 c.3471_3474delGAGA p.Glu1157fs 1
15F 1166 c.3497dupA p.Tyr1166fs 1
15F 1167 c.3501_3504delTGAA p.Asn1167fs 1
15F 1168 c.3502G>T p.Glu1168X 2
15F 1169 c.3505_3509delGAGAA p.Glu1169fs 1
15F 1186 c.3556_3557 delGA p.Asp1186fs 1
15F 1187 c.3559dupA p.Ile1187fs 2
15F 1193 c.3577_3578delCA p.Gln1193fs 1
15F 1194 c.3581C>A p.Ser1194X 1
15F 1194 c.3581C>G p.Ser1194X 1
15F 1196 c.3587C>A p.Ser1196X 1
15F 1198 c.3593C>G p.Ser1198X 1
15F 1199 c.3595_3596delAA p.Lys1199fs 4
15F 1201 c.3602C>G p.Ser1201X 1
15F 1209 c.3625_3628delGAAC p.Glu1209fs 1
15F 1222 c.3666_3679del14 p.Ser1222fs 1
15F 1230 c.3688C>T p.Gln1230X 1
15F 1244 c.3730C>T p.Gln1244X 1
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Exon/Intron Codon Mutation Consequence Number 
of alleles
15F 1249 c.3747C>A p.Cys1249X 1
15F 1250 c.3749_3750delAA p.Lys1250fs 1
15F 1256 c.3768dupA p.Glu1257fs 1
15F 1262 c.3786T>A p.Tyr1262X 1
15F 1267 c.3796_3799dupGATA p.Thr1267fs 2
15F 1268 c.3803_3815del13 p.Pro1268fs 1
15F 1269 c.3805delA p.Ile1269fs 1
15F 1269 c.3806dupT p.Ile1269fs 1
15G 1270 c.3810_3811insC p.Phe1270fs 1
15G 1272 c.3816_3817ins14 p.Arg1272fs 1
15G 1275 c.3824_3831delGTTCATTA p.Ser1275fs 1
15G 1278 c.3833C>A p.Ser1278X 1
15G 1286 c.3856G>T p.Glu1286X 1
15G 1294 c.3880delC p.Gln1294fs 1
15G 1298 c.3892_3903del12insATTT p.Ser1298fs 1
15G 1309 c.3925G>T p.Glu1309X 2
15G 1309 c.3925-3928delGAAA p.Glu1309fs 5
15G 1309 c.3927_3931delAAAGA p.Glu1309fs 56
15G 1321 c.3963delC p.Ser1321fs 1
15G 1338 c.4012C>T p.Gln1338X 1
15G 1341 c.4022delG p.Ser1341fs 1
15G 1341 c.4022_4023ins22 p.Ser1341fs 2
15G 1342 c.4025dupT p.Leu1342fs 2
15G 1344 c.4031C>G p.Ser1344X 1
15H 1367 c.4099C>T p.Gln1367X 2
15H 1376 c.4128delT p.Tyr1376fs 1
15H 1376 c.4127_4128delAT p.Tyr1376fs 1
15H 1378 c.4132C>T p.Gln1378X 1
15H 1381 c.4142dupC p.His1381fs 1
15H 1400 c.4199C>A p.Ser1400X 1
15H 1425 c.4273delGA p.Asp1425fs 1
15H 1426 c.4275dupT p.Ser1426fs 1
15H 1432 c.4295delC p.Pro1432fs 1
15H 1444 c.4331C>T p.Gln1444X 1
15H 1450 c.4348C>T p.Arg1450X 5
15H 1451 c.4351G>T p.Glu1451X 1
15H 1455 c.4364_4368delATAAA p.Asn1455fs 1
15H 1459 c.4377delT p.Thr1459fs 1
15H 1461 c.4383_4387delAAAGA p.Lys1461fs 1
15H 1462 c.4385delA p.Arg1462fs 1
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Exon/Intron Codon Mutation Consequence Number 
of alleles
15H 1464 c.4391_4394delAGAG p.Glu1464fs 3
15H 1465 c.4393_4394delAG p.Ser1465fs 8
15I 1495 c.4483delA p.Ser1495fs 1
15I 1496 c.4487dupC p.Thr1496fs 1
15I 1498 c.4492del G p.Asp1498fs 1
15I 1516 c.4547_4548delTA p.p.Ile1516fs 1
15I 1517 c.4549C>G p.Gln1517X 2
15I 1522 c.4570_4576del7 p.Ile1522fs 1
15I 1531 c.4592dupA p.Met1531fs 1
15I 1538 c.4612_4613delGA p.Glu1538fs 2
15I 1541 c.4621C>T p.Gln1541X 1
15I 1545 c.4634C>G p.Ser1545X 1
15I 1548 c.4643delA p.Asn1548fs 1
15I 1551 c.4652_4655delAAGA p.Lys1551fs 2
15I 1556 c.4666delA p.Thr1556fs 1
15I 1556 c.4666dupA p.Thr1556fs 3
15I 1563 c.4688_4703del16 p.Leu1563fs 1
15I 1565 c.4694T>A p.Leu1565X 1
15I 1567 c.4700C>G p.Ser1567X 1
15I 1578 c.4733_4734delGT p.Cys1578fs 1
15I 1581 c.4741dupT p.Leu1581fs 1
15I 1596 c.4786delC p.Gln1596fs 4
15I 1600 c.4799_4800dupAA p.Asn1600fs 1
15J 1628 c.4883delA p.Lys1628fs 1
15J 1652 c.4954delT p.Ser1652fs 1
15J 1661 c.4982_4983insTA p.Thr1661fs 1
15J 1683 c.5047G>T p.Glu1683X 1
15L 1823 c.5471delA p.Asn1823fs 1
15N 1958 c.5873delA p.Asn1958fs 2
15N 1973 c.5917delA p.Ser1973fs 1
15N 1981 c.5943_5946delTAAA p.Ile1981fs 1
15M 1983 c.5947_5950delGAAA p.Glu1983fs 1
15N 1984 c.5952_5955delTGAA p.Asn1984fs 1
15N 1986 c.5957delC p.Pro1986fs 1
15N 1993 c.5978delC p.Pro1993fs 1
15P 2117 c.6351delA p.Gln2117fs 1
15P 2192 c.6574A>T p.Lys2192X 1
15T 2557 c.7671_7678delCCTTCCTC p.Ser2557fs 1
* These missense or silent mutations result in exon splicing [19]
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1309 mutation increases to 10% (54/537). The
mutation occurs at high frequency de novo: in 22 of
the 56 index patients (39%) the 5 bp deletion at codon
1309 was excluded in both parents [17]. In the two
patients diagnosed at ages of 43 and 53, the mutation
had occurred de novo as well. This mutation was also
reported at high frequencies in patients from Japan,
Singapore and South Africa [23-25] and at moderate
proportions in most European populations [26-29],
but – interestingly – it has not been found in patient
groups from Australia or Spain [30, 31]. 
The hot spot mutation c. 3183_3187delACAAA (at
codon 1061) was detected in 43 index patients: 3.7%
of all patients and 7.1% (36/504) in the group of
patients with typical FAP. This mutation occurred de
novo in 7 of the 43 index patients (16.3%). 
Mutation detection rate according 
to phenotype and family history
APC mutation detection rates in FAP patients
varying between 30-85% have been published 
[26-29, 32]. For evaluation of the APC mutation
detection rate and prevalence of mutations it is
worthwhile to consider the colorectal phenotype and
the family history of index patients examined for
mutations. Overall, point mutations and large
deletions in the APC gene were detected in 634 of
the 1166 index patients (54%) (Table 1). The
mutation detection rate was 82% in patients with
typical FAP, but only 24% in patients with AAPC.
Remarkably, 30 of the large genomic deletions (81%)
occurred in patients with typical FAP. 
Fig. 1. Distribution of 597 germline point mutations and 37 large deletions in the APC gene detected in 634 out of 1166 unrelated FAP
patients. A schematic diagram presents the promotor region (P) and the 15 exons of the APC gene. The black horizontal bars represent
the extent of deletions as determined by MLPA, and the numbers on the left side of the bars indicate the deletions that have been identified
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Table 2. Relationship between the site of mutation in the APC gene and CHRPE status in 413 FAP patients from 285 families. The patients
whose CHRPE status conforms to the published correlation are printed in bold.
Site of APC mutation Predicted CHRPE status Number of patients Number of patients Number of patients
(Codon) examined for CHRPE with CHRPE without CHRPE
122-414 CHRPE-negative 52 (39) ** 6 (6) 46 (34) 
423-1367 CHRPE-positive 307 (205) 244 (156) 63 (58) 
1451-2557 CHRPE-negative 34 (29) 3 (3) 31 (28) 
large deletions* ? 20 (12) 15 (9) 5 (5) 
all patients 413 (285) 268 (174) 145 (118) 
*Patients with large deletions encompassing the whole gene were in both CHRPE-positive and CHRPE-negative groups.
**The numbers of families are shown in parentheses. In some families a discrepant CHRPE status was observed.
The distribution of patients according to family
history and the corresponding mutation detection rates
are presented in Table 1. As expected, the mutation
detection rate increases in all patient groups when only
familial cases with an autosomal-dominant mode of
inheritance are considered (Table 1). The mutation
detection rate in cases with de novo mutations is – by
our definition – 100%. Most of the patients with a de
novo mutation had developed typical FAP. 
Genotype-phenotype correlations
For evaluation of the correlation between the site
of mutation in the APC gene and different colonic and
extracolonic manifestations we included clinical
information obtained from 2066 patients from the
1166 families. 
CHRPE
Presence of CHRPE has been reported in patients
with mutations 3' to exon 9 [9, 10] but not beyond codon
1444 [8, 33]. However, isolated cases constituting
exceptions to this 'rule' have also been published [34]. 
Information on the results of retinal examination
was available for 413 patients from 285 families with
known germline mutations (Table 2). Since patients with
mutations in exon 9 were published both with and
without CHRPE, we defined the limit of the region
characteristic for CHRPE in codon 410, the first codon
outside the alternatively spliced sequence of exon 9. 
Overall, CHRPE was detected in 268 of the 413
patients (65%), including 15 patients from 9 families
with large deletions. 244 of the 253 CHRPE-positive
patients with point mutations in the APC gene (96%)
had mutations between codons 423-1367. However,
63 of the 307 patients with mutations in this part of the
gene (21%) did not present CHRPE, and thus do not
conform to the previously published correlation. On the
other hand, 76 out of the 85 patients (89%) with
mutations between codons 122-414 or 1451-2557 did
not have CHRPE; thus, only nine patients did not
conform to the published rule. CHRPE was detected in
15 out of 20 patients with large deletions. Of note,
deletions of the entire APC gene were detected in both
CHRPE-positive and CHRPE-negative groups. 
Taken together, the previously published correlation
between site of mutation and expression of CHRPE was
confirmed in our large group of patients, but overall
18% of patients with point mutations (63+9/393) do
not conform to the rule. Part of this deviation might be
explained by the fact that some patients were seen by
ophthalmologists who are not aware of the different
types of CHRPE, including even small retinal lesions
[35]. However, intrafamilial discrepant observations
were also found in some patients who were examined
by an ophthalmologist experienced in diagnosis of
CHRPE over several years. Of note, 12 out of the 63
CHRPE-negative patients (19%) with mutations within
codons 423-1367, but only 21 of the 244
CHRPE-positive patients (9%) had a de novo mutation
(p=0.023; Fisher's exact test, two sided), suggesting
that CHRPE may not be expressed in some patients with
de novo mutations because of somatic mosaicism. 
Colorectal phenotype
According to data from the literature, a severe clinical
phenotype is associated with mutations at codon 1309
[7, 12], and an attenuated FAP is observed in patients
with mutations 5' to codon 168 [6], in the alternatively
spliced sequence of exon 9 [11, 36-39] or 3' to codon
1580 [40-42] while typical FAP is observed in patients
with mutations at the remaining sites. 
Progression of colorectal disease in FAP patients is
a continuous process. Therefore, evaluation of the
severity of the disease is largely dependent on time of
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Supplementary table 2. Large deletions detected in 37 out of 1166 unrelated patients suspected of FAP
Deleted exons Genomic deletion GenBank AC008575.7 Number of alleles
Cytogenetic deletion cytogenic 1
Promotor and whole gene g.26940-?_133343+?del 16
Promotor and exon 1 g.26940-?_44326+?del 1
Promotor and exon 1-5 g.26940-?_70201+?del 1
Promotor and exon 1-7 g.26940-?_90721+?del 1
Promotor and exon 1-10 g.26940-?_111301+?del 1
Exon 1-15 end g.44326-?_133343+?del 2
Exon 2-15 end g.55780-?_133343+?del 1
Exon 4 g.65700-?_66200+?del 1
Exon 5-15 end g.70201-?_133343+?del 1
Exon 8-15 end g.104881-?_133343+?del 1
Exon 9-15 end g.108601-?_133343+?del 1
Exon 11 g.115000-?_116900+?del 1
Exon 11-12 g.116521-?_1117361+?del 2
Exon 11-15 end g.116521-?_133343+?del 1
Exon 14 g.123900-?_125100+?del 2
Exon 14-15 middle g.123900-?_129830+?del 1
Exon 14-15 end g.123900-?_133343+?del 1
Exon 15 middle - 15 end g.129830-?_133343+?del 1
diagnosis. The most accurate parameters for evaluation
of the natural course of the disease would be the age
at occurrence of the first colonic adenomas and the
age-related number of polyps. However, these data are
available only for a small number of mutation carriers
who started with regular colonoscopies at an early age. 
Age at diagnosis of adenomas in asymptomatic
mutation carriers who underwent endoscopic screening
is not a suitable parameter as it depends on the time of
the first endoscopy and whether surveillance is regularly
performed. Therefore, we used the age at diagnosis of
FAP in patients who developed gastrointestinal symptoms
(rectal bleeding, diarrhoea, etc.) prior to the first
endoscopies as a parameter for the severity of the
colorectal phenotype [28]. Age at diagnosis of FAP was
known in 760 patients who were diagnosed after the
onset of bowel symptoms (Fig. 2). The mean age at
diagnosis in these patients was 35 years (range 3-78
years). Germline mutations in the APC gene were
identified in 485 of the 760 patients diagnosed because
of bowel symptoms. We confirmed in these patients the
correlation between APC mutation site and mean age
at diagnosis of FAP (Fig. 2). Patients with a mutation at
codon 1309 developed bowel symptoms more than 10
years earlier (20 years of age) compared with patients
with other mutations: 50 years of age in patients with
mutations at sites characteristic of AAPC, 32 years of
age in patients with mutations at other sites and 41 years
of age in patients with no identified APC mutation
(p<0.001 for all comparisons; two-sided Student's t-
test). The 32 patients with large genomic deletions had
a mean age at diagnosis of 33 years, comparable to
that of patients with mutations characteristic of typical
FAP (p=0.38). Despite this significant correlation
a considerable variation of age at diagnosis in patients
with the same mutation or even within the same family
was observed, as we had illustrated for part of this
patient group in a previous report [28]. 
As another parameter for severity of the disease we
used the clinical phenotype classification that takes
into account the age-related polyp number in addition
to the age at diagnosis (see phenotype classification).
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When grouping the 2066 patients according to the
clinical phenotype and the mutation intervals outlined
above, most patients conformed to the published
genotype-phenotype correlation (Table 3): 84 of the
101 patients with mutations at sites characteristic of
AAPC (83%) were classified as having an attenuated
phenotype, and another 8 patients had an atypical
phenotype. Accordingly, 80% of patients with mutations
at sites characteristic of typical FAP (587/735) were
classified as having a typical FAP phenotype. Only 34%
(28/83) of patients with mutations at codon 1309 were
classified as having a severe phenotype, whereas 63%
(52/83) had typical FAP. 
Influence of mutation type on clinical phenotype
The genotype-phenotype correlations presented
here and in reports on other patient groups roughly
consider only the site and not the type of mutations.
When we looked in more detail at mutations between
codons 170-1578 in the 68 patients with attenuated
phenotype who did not conform with the expected
genotype-phenotype correlation, we observed some
distinctive features. 
In this patient group there was an unexpectedly high
proportion of splice site mutations: 20/68=29% in
patients with attenuated phenotype vs. 25/587=4% in
patients with typical phenotype (p<0.001; Fisher's exact
test, two sided). Some of these splice site mutations
may lead to in-frame deletions or to partial exon
deletions. We present some examples: we showed by
RNA analysis that the substitution c.1312+3A>G in
intron 9 detected in two unrelated patients with
attenuated phenotype leads to partial loss of exon 9,
while the substitution at position +5 of this intron
(c.1312+5G>A) detected in a family with typical FAP
leads to complete loss of exon 9. Moreover, the
substitution at the highly conserved position -2 in intron
14 (c.1959-2A>G) is predicted to result in a splicing
Genotype-Phenotype Correlations in FAP
Fig. 2. Box plot showing the relationship between the mutation site
in the APC gene and age at diagnosis (achieved after bowel
symptoms had developed) in 485 patients with known mutations
and 275 patients with unknown mutations. The black horizontal bars







































Table 3. Grouping of patients classified according to the site of APC mutation and colorectal phenotype. The numbers of patients with the
expected phenotype at the respective germline mutation region are printed in bold
Colorectal phenotype
Site of APC mutation Predicted All patients known severe typical atypical attenuated unknown
(Codon) phenotype
122-161
314-405 Attenuated FAP 146 101 9 8 84 45
1581-2557
170-1578 Typical FAP 1059 735 34 587 46 68 324
without 1309
1309 Severe FAP 96 83 28 52 1 2 13
Large deletions ? 78 67 57 4 6 11
No mutation ? 687 540 12 123 52 353 147
All 2066 1526 74 828 111 513 540
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defect. RNA analysis demonstrated a partial use of
a cryptic splice site 12 bp downstream, resulting in
a slightly shortened in-frame transcript and likely to
lead to a functional APC protein [19]. 
Somatic mosaicism in patients with de novo mutations
may be another reason for an attenuated phenotype. In
two patients the nonsense mutations p. Arg216X and p.
Gln1127X, respectively, were detected in blood samples
only as faint signals, suggesting in these cases the
presence of a somatic mosaic in the blood and possibly
in the colonic epithelium. In the two patients with the 5 bp
deletion at codon 1309 and an attenuated phenotype
the mutation had occurred de novo; the mutant alleles
were detected in their blood samples at normal levels
(comparable to familial cases) but may be present as
somatic mosaics in the intestinal epithelium. 
While these examples can explain only some of the
cases of nonconformity with the established
genotype-phenotype correlations, they demonstrate
that mutational consequences may be different even
if mutations occur in the immediate vicinity of one
another. Since the majority of mutations are truncating
and most cases of possible mosaicism affect only the
first generation, exceptions to the otherwise consistent
genotype-phenotype correlations are relatively rare. 
Modifier genes
The intrafamilial variability frequently observed in
large multigeneration FAP families [41, 43-45] cannot
be explained by the reasons outlined above. Variations
in other genes acting as modifiers at the level of APC
synthesis and function or on other regulatory proteins
in Wnt signalling and cell adhesion are discussed as
causative factors of phenotypic variability within families
or in patients with the same germline mutation. In
animal experiments a variant in the secretory type II
phospholipase A2 gene (Pla2s) designed as MOM1
(modifier of Min) has been proven as the first modifier
influencing the number of intestinal polyps in Min mice
[46]. Discordant findings regarding the existence of
a modifying locus for severity of colonic or extracolonic
manifestations in FAP on human chromosome 1p35-
36, the region synthenic with the Pla2s locus on mouse
chromosome 4, have been published [47-50].
Moreover, polymorphisms in enzymes playing a role in
different metabolic and cell cycle controlling pathways,
e.g. N-acetyl transferase type 1 and 2, glutathione 
S-transferases M1 amd T1, and others, have been
examined for possible modifying effects on
gastrointestinal and extragastrointestinal symptoms 
[47-50]; however, no concordant results were obtained. 
Desmoid disease and osteomas
A higher frequency of desmoid tumours and
osteomas has been repeatedly observed in FAP patients
with a germline mutation 3' to codon 1444 [8, 51].
Moreover, several families with mutations in the 3' part
of the APC gene who developed desmoids in the
absence of polyposis or with a very mild polyposis
phenotype have been described [52, 53]. 
In our patient sample presence or absence of
desmoids and osteomas was only occasionally
reported in the medical records, and we have not
specifically asked for this information during the last
few years. Therefore, our data on these extracolonic
manifestations are mainly similar to those previously
published [28]. The actual data are presented in Table
4. Information on desmoid and osteoma status was
obtained from 380 and 195 patients with identified
mutations, respectively. From these data it becomes
evident that in a retrospective study like ours, where
patients are not explicitly examined for desmoids or
osteomas, there must be a selection bias: the presence
of clinically manifest desmoids or osteomas in patients
is more likely to be documented as compared to their
absence. Therefore, when calculating the presence of
these extracolonic manifestations on the basis of
patients with documented disease status, the values
are too high. We believe that the proportions
calculated on the basis of all patients with mutations
in different APC regions (figures given in parentheses
in Table 4) better reflect the real situation regarding
the presence of these extracolonic features. Even with
this rough estimation the higher proportion of desmoids
and osteomas in patients with mutations 3' to codon
1444 remains evident. Of note, CHRPE status is not
so much affected by this selection bias, because
determination of the presence or absence of CHRPE
requires a special ophthalmological examination. 
Conclusion
The discovery of the molecular basis of FAP by
identification of germline mutations in the APC gene
in polyposis patients has stimulated the interest of
clinicians and molecular biologists in this disease.
During the last years several groups of polyposis
patients have been examined for mutations in the APC
gene. APC mutation detection rates in FAP patients
varying between 30-85% have been published. This
variation largely depends on patient selection and their
clinical phenotype: the discovery that attenuated FAP
is also caused by germline mutations in the APC gene
has increased the proportion of patients with few
adenomas irrespective of the family history among
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Table 4. Distribution of patients according to the site of APC mutation and the presence or absence of desmoids and osteomas
Site of mutation
All 5' to codon 1444 3' to codon 1444 large deletions
All patients 1379 1169 132 78
Desmoids
present 76 52 19 5
absent 304 267 22 15
all* 380 319 41 20
% desmoids 20% 16% 46% 25%
% desmoids (minimal estimate)** (5%) (4%) (14%) (6%)
Osteomas
present 65 36 28 1
absent 130 115 8 7
all* 195 151 36 8
% osteomas 33% 23% 78% 12%
% osteomas (minimal estimate)** (5%) (3%) (21%) (1%)
*number of patients with records regarding presence or absence of desmoids/osteomas
**Because of a selection bias towards patients with expressed desmoids or osteomas, a minimal estimate was calculated based on the documented presence of the respective extracolonic
manifestations in all patients.
patients examined for mutations. This has led to an
overall decrease in the mutation detection rate. Our
data show mutation detection rates up to 85% when
patients with typical FAP are considered. 
Impressive correlations between the site of mutations
in the large APC gene and the clinical phenotype
including both the colonic polyposis phenotype and
manifestation of extracolonic features have been
published. Examination for CHRPE had been proposed
as a useful marker for pointing to the gene region that
should be examined for APC mutations. In addition,
CHRPE status was thought to be used for predictive
testing in families with no identified APC mutation, but
where the index patient presents with CHRPE. However,
findings of intrafamilial discrepancies in CHRPE status
limit its use as a predictive marker in persons at risk.
Moreover, due to the absence of CHRPE in most
patients with an attenuated polyposis phenotype,
ophthalmogical examinations are of little value in the
actual diagnostic procedure. 
The association of attenuated FAP with APC
mutations localised in the 5' or 3' part of the gene or in
the alternatively spliced region of exon 9 has also
repeatedly been published and has been, in principle,
confirmed in our sample of 1379 patients with known
APC mutations. When examining this correlation it
should be kept in mind that classification of the clinical
phenotype into typical and attenuated FAP may be
difficult in some cases. This classification is based ideally
on the age at onset of polyp growth and age-related
polyp numbers, but in most cases these data are not
available because patients are diagnosed at different
stages of disease development. On the other hand, the
type of mutation may also play a role and may explain
some exceptions to the expected relationship. In
addition, even intrafamilial variation of the clinical
phenotype has been described, pointing to the presence
of other genetic or environmental factors. Therefore,
identification of the APC mutation in a patient is of
limited value for the prediction of the clinical course of
the disease or for therapeutic decisions. 
The discovery of MUTYH-associated polyposis
(MAP) due to biallelic mutations in the MUTYH gene
has complicated our perception of adenomatous
polyposis. Initially it was thought that all cases of
adenomatous polyposis follow an autosomal-dominant
mode of inheritance and are caused by mutations in
the APC gene, irrespective of whether or not the
mutation was identified. The existence of an
autosomal-recessive polyposis disease that clinically
resembles FAP implies that some statements regarding
risk predictions in the families based on indirect
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genotype analysis or apparent de novo mutations have
to be reevaluated. The frequency of MUTYH-associated
polyposis among unselected APC-mutation-negative
polyposis patients ranges between 15% and 40%. 
In this context the search for an APC mutation,
especially in patients without a family history of FAP, is
of importance for defining the recurrence risk in their
families. However, mutation analysis is still laborious
and expensive, and even with more up-to-date and
sophisticated methods a mutation in the APC (or
MUTYH) gene(s) cannot be excluded. Moreover, as
other polyposis syndromes (e.g. familial juvenile
polyposis or Peutz Jeghers syndrome, caused by
mutations in other genes) have to be considered as
differential diagnoses, we would like to emphasise the
importance of the clinical diagnosis including polyp
number, site of location in the colorectum and
histology, and family history prior to requesting
molecular diagnostics. These data, especially polyp
histology, are necessary in order to differentiate
between different types of polyposis and to provide
mutation analysis of the appropriate genes. 
The identification of the underlying germline
mutation(s) in polyposis patients allows predictive
diagnostics in persons at risk in their families. Genetic
counselling should be offered to the patients and their
families in order to explain the complex picture of
polyposis disease, including the possibilities and
limitations of molecular diagnostics for surveillance
and therapy. 
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